These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25726180)

  • 1. Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus.
    Badalzadeh R; Mokhtari B; Yavari R
    J Physiol Sci; 2015 May; 65(3):201-15. PubMed ID: 25726180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures.
    Sanada S; Komuro I; Kitakaze M
    Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H1723-41. PubMed ID: 21856909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus.
    Lejay A; Fang F; John R; Van JA; Barr M; Thaveau F; Chakfe N; Geny B; Scholey JW
    J Mol Cell Cardiol; 2016 Feb; 91():11-22. PubMed ID: 26718721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury.
    Ong SB; Samangouei P; Kalkhoran SB; Hausenloy DJ
    J Mol Cell Cardiol; 2015 Jan; 78():23-34. PubMed ID: 25446182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling mediators modulated by cardioprotective interventions in healthy and diabetic myocardium with ischaemia-reperfusion injury.
    Saeid F; Aniseh J; Reza B; Manouchehr VS
    Eur J Prev Cardiol; 2018 Sep; 25(14):1463-1481. PubMed ID: 29442529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.
    Ferdinandy P; Andreadou I; Baxter GF; Bøtker HE; Davidson SM; Dobrev D; Gersh BJ; Heusch G; Lecour S; Ruiz-Meana M; Zuurbier CJ; Hausenloy DJ; Schulz R
    Pharmacol Rev; 2023 Jan; 75(1):159-216. PubMed ID: 36753049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria "THE" target of myocardial conditioning.
    Boengler K; Lochnit G; Schulz R
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1215-H1231. PubMed ID: 30004243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postconditioning--A new link in nature's armor against myocardial ischemia-reperfusion injury.
    Vinten-Johansen J; Zhao ZQ; Zatta AJ; Kin H; Halkos ME; Kerendi F
    Basic Res Cardiol; 2005 Jul; 100(4):295-310. PubMed ID: 15793629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning.
    Heusch G
    Circ Res; 2015 Feb; 116(4):674-99. PubMed ID: 25677517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What makes the mitochondria a killer? Can we condition them to be less destructive?
    Murphy E; Steenbergen C
    Biochim Biophys Acta; 2011 Jul; 1813(7):1302-8. PubMed ID: 20837069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Past and present course of cardioprotection against ischemia-reperfusion injury.
    Liem DA; Honda HM; Zhang J; Woo D; Ping P
    J Appl Physiol (1985); 2007 Dec; 103(6):2129-36. PubMed ID: 17673563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous cardioprotection by ischaemic postconditioning and remote conditioning.
    Shi W; Vinten-Johansen J
    Cardiovasc Res; 2012 May; 94(2):206-16. PubMed ID: 22323534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotection of ischemic postconditioning and pharmacological post-treatment with adenosine or acetylcholine.
    Zang WJ; Sun L; Yu XJ
    Sheng Li Xue Bao; 2007 Oct; 59(5):593-600. PubMed ID: 17940699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological pre- and post- conditioning agents: reperfusion-injury of the heart revisited.
    Andreadou I; Iliodromitis EK; Koufaki M; Kremastinos DT
    Mini Rev Med Chem; 2008 Aug; 8(9):952-9. PubMed ID: 18691153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation.
    Clarke SJ; Khaliulin I; Das M; Parker JE; Heesom KJ; Halestrap AP
    Circ Res; 2008 May; 102(9):1082-90. PubMed ID: 18356542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RISK pathway leading to mitochondria and cardioprotection: how everything started.
    Yellon DM; Beikoghli Kalkhoran S; Davidson SM
    Basic Res Cardiol; 2023 May; 118(1):22. PubMed ID: 37233787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury.
    Bell RM; Yellon DM
    Cardiovasc Ther; 2011 Dec; 29(6):e67-79. PubMed ID: 20645988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Myocardial Ischemia/Reperfusion Injury by Ischemic and Pharmacological Postconditioning.
    Heusch G
    Compr Physiol; 2015 Jul; 5(3):1123-45. PubMed ID: 26140711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preconditioning and postconditioning: united at reperfusion.
    Hausenloy DJ; Yellon DM
    Pharmacol Ther; 2007 Nov; 116(2):173-91. PubMed ID: 17681609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.